切换至 "中华医学电子期刊资源库"

中华临床实验室管理电子杂志 ›› 2021, Vol. 09 ›› Issue (03) : 164 -168. doi: 10.3877/cma.j.issn.2095-5820.2021.03.008

实验研究

小体积核酸样本检测晚期非小细胞肺癌患者外周血表皮生长因子受体突变的可行性及应用
徐韫健1, 王建平2, 林勇平1,(), 姜桔红1   
  1. 1. 510120 广东广州,广州医科大学附属第一医院
    2. 510530 广东广州,广州市宝创生物技术有限公司
  • 收稿日期:2021-01-19 出版日期:2021-08-26
  • 通信作者: 林勇平
  • 基金资助:
    国家自然科学基金项目(81772814)

Feasibility and application of small volume nucleic acid sample to detect the EGFR mutation in peripheral blood from patients with advanced non-small cell lung cancer

Yunjian Xu1, Jianping Wang2, Yongping Lin1,(), Juhong Jiang1   

  1. 1. Department of Clinical Laboratory, The First Affiliated Hosptital of Guangzhou Medical University, Guangzhou Guangdong 510120, China
    2. Guangzhou Baochuang Biotechnology Co., Ltd., Guangzhou Guangdong 510530, China
  • Received:2021-01-19 Published:2021-08-26
  • Corresponding author: Yongping Lin
引用本文:

徐韫健, 王建平, 林勇平, 姜桔红. 小体积核酸样本检测晚期非小细胞肺癌患者外周血表皮生长因子受体突变的可行性及应用[J/OL]. 中华临床实验室管理电子杂志, 2021, 09(03): 164-168.

Yunjian Xu, Jianping Wang, Yongping Lin, Juhong Jiang. Feasibility and application of small volume nucleic acid sample to detect the EGFR mutation in peripheral blood from patients with advanced non-small cell lung cancer[J/OL]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2021, 09(03): 164-168.

目的

评价一种操作便捷,小体积核酸样本即可满足外周血表皮生长因子受体(EGFR)突变检测的方法。

方法

采用新型ctDNA检测试剂盒,对94例临床小体积核酸样品(样本使用量为临床样本量的1/9)进行检测分析;另外随机选取46例临床检测(ARMS法)EGFR突变为阳性的样本,取剩余的临床核酸样本进行验证,进而研究该检测试剂盒结果与ARMS检测结果的一致性;对于不一致的结果采用SuperARMS法进行验证。

结果

与ARMS法检测结果相比较,小样本量检测的94例样本符合率为93.6% (88/94),阳性符合率82.1% (23/28),阴性符合率为98.7% (65/66);46例EGFR突变阳性的样本中,两种检测方法符合率为97.8%。

结论

新型ctDNA检测试剂盒与ARMS法有较高一致性,该结果提示,在样本量较少的情况下,新型ctDNA检测EGFR突变具有潜在可行性。

Objective

To evaluate a convenient method for detecting EGFR mutations with small volume of nucleic acid samples.

Methods

A new ctDNA (circulate tumor DNA) detection kit was used to detect and analyze the remaining clinical samples with a total of 94 samples, and the sample amount was 1/9 of the clinical sample size. In addition, 46 samples with positive EGFR mutation in clinical detection (ARMS method) were randomly selected, and the remaining clinical samples were taken for DNA co-locus detection, so as to study the consistency between the detection results and the clinical results. The inconsistent results were verified by SuperARMS method.

Results

Compared with the results of ARMS test, the total coincidence rate was 93.6% (88/94), the positive coincidence rate was 82.1% (23/28) and the negative coincidence rate was 98.7% (65/66). In 46 EGFR mutation positive samples, the coincidence rate of the two methods was 97.8%.

Conclusions

The new ctDNA detection kit has a high consistency with ARMS method, which suggests that the new ctDNA detection for EGFR mutations is potentially feasible in the case of a small sample size.

图1 患者入组及检测分组示意图
表1 临床资料与阳性检测结果
表2 两种试剂盒样本检测结果对比(例)
表3 两种试剂盒检测突变类型的对比(例)
表4 阳性位点检测的一致性比较结果(例)
1
Ettinger DS, Wood DE, Aggarwal C, et al. NCCN Guidelines Insights: Non-Small Cell Lung Cancer[J]. J Natl Compr Canc Netw, 2019, 17(12):1464-1472.
2
Lee DH. Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a success, paved with failures[J]. Pharmacol Ther, 2017, 174:1-21.
3
Heidrich I, Ackar L, Mossahebi Mohammadi P, et al. Liquid biopsies: Potential and challenges[J]. Int J Cancer, 2021, 148(3):528-545.
4
中国非小细胞肺癌患者EGFR T790M基因突变检测专家组. 中国非小细胞肺癌患者EGFRT790M基因突变检测专家共识[J]. 中华医学杂志, 2018, 98(32):2544-2548.
5
Wu YL, Lee V, Liam CK, et al. Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies[J]. Lung Cancer, 2018, 126:1-8.
6
非小细胞肺癌血液EGFR基因突变检测中国专家组. 非小细胞肺癌血液EGFR基因突变检测中国专家共识[J]. 中华医学杂志, 2015, 46(95):3721-3726.
7
Oxnard GR, Hu Y, Mileham KF, et al. Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib[J].JAMA Oncol, 2018, 4(11):1527-1534.
8
张萌, 孟昭婷, 张翠翠, 等. Super-ARMS法检测EGFR突变在NSCLC的临床应用[J]. 天津医科大学学报, 2021, 27(2):185-187, 203.
9
Liang Z, Cheng Y, Chen Y, et al. EGFR T790M ctDNA testing platforms and their role as companion diagnostics: Correlation with clinical outcomes to EGFR-TKIs[J]. Cancer Lett, 2017, 403:186-194.
10
Wu W, Cao Z, Zhang W, et al. Comparison of the Super ARMS and ARMS for detecting EGFR mutations in liquid-based cytology specimens from NSCLC patients[J]. Diagn Pathol, 2020, 15(1):9.
11
CaoZY, WuW, HouLK, et al. Comparison of epidermal growth factor receptor (EGFR) gene T790M mutation by droplet digital PCR and Super-ARMS PCR in plasma ctDNA samples of non-small cell lung cancer patients with the resistance to EGFR-tyrosine kinase inhibitor[J]. 中华病理学杂志, 2018, 47(12):910-914.
12
Zou B, Cao X, Wu H, et al. Sensitive and specific colorimetric DNA detection by invasive reaction coupled with nicking endonuclease-assisted nanoparticles amplification [J].Biosens Bioelectron, 2015, 66:50-54.
13
Zou B,Song Q, Wang J, et al. Invasive reaction assisted strand-displacement signal amplification for sensitive DNA detection[J]. Chem Commun (Camb), 2014, 50(89):13722-13724.
[1] 铁晓玲, 刘毅, 杨颖, 车凤玉. Rubinstein-Taybi综合征先证者3例并文献复习[J/OL]. 中华妇幼临床医学杂志(电子版), 2024, 20(04): 452-459.
[2] 杨慧, 郭丽娟, 冯晓丹, 李静, 黄成谋, 蔡兴锐, 覃英娇, 王远礼. 非小细胞肺癌铂类药物耐药mi RNA表达特征及预测分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 719-724.
[3] 赖淼, 景鑫, 李桂珍, 李怡. 非小细胞肺癌EGFR 突变亚型的临床病理和预后意义[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 731-737.
[4] 梁丽斯, 李洁, 贺帅, 来艳君, 刘铭, 张琳. MMP-9、MMP-2 及TLR4、HE4对非小细胞肺癌早期诊断意义[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 756-761.
[5] 张礼江, 沈玲佳, 施我大. 倾向性评分匹配分析奥希替尼对晚期NSCLC 预后的影响[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 820-822.
[6] 赵蒙蒙, 黄洁, 余荣环, 王葆青. 过表达小GTP酶Rab32抑制非小细胞肺癌细胞侵袭性生长[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(04): 512-518.
[7] 张桂萍, 丘勇林, 湛绮婷, 孙乐栋. 晚期非小细胞肺癌血清Ape1/Ref-1对放射性肺损伤发生的预测意义[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(04): 519-523.
[8] 韩晓宇, 李柯育, 赵志菲, 高建平. SNHG17过表达对非小细胞肺癌切除术预后的意义[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(04): 543-547.
[9] 刘松, 张进召, 贾艳云. 帕博利珠单抗治疗晚期非小细胞肺癌反应降低与抗生素预处理的关系[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(04): 553-557.
[10] 李多, 郝昭昭, 陈延伟, 南岩东. 血清PTX3表达与非小细胞肺癌骨转移的相关性分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(04): 558-562.
[11] 刘文竹, 唐窈, 刘付臣. 诱导多潜能干细胞在神经肌肉疾病研究中的应用进展[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(06): 367-373.
[12] 李玺, 蔡芸莹, 张永红, 苏恒. 假性软骨发育不全合并1型糖尿病一例[J/OL]. 中华临床医师杂志(电子版), 2024, 18(05): 518-520.
[13] 崔伟, 邓屹, 叶苏意, 李静, 陈晓明, 张靖, 许荣德. 载药微球支气管动脉化疗栓塞术治疗罕见非小细胞肺癌的临床疗效和安全性分析[J/OL]. 中华介入放射学电子杂志, 2024, 12(04): 303-310.
[14] 崔伟, 叶苏意, 邓屹, 陈晓明, 张靖, 李静, 许荣德. 载药微球支气管动脉化疗栓塞术治疗难治性非小细胞肺癌的临床疗效及安全性[J/OL]. 中华介入放射学电子杂志, 2024, 12(04): 311-316.
[15] 蔡剑桥, 蒋雷. 单孔胸腔镜与开胸双袖式肺叶切除治疗非小细胞肺癌对比[J/OL]. 中华胸部外科电子杂志, 2024, 11(04): 225-230.
阅读次数
全文


摘要